• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Dashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlerts
    Company
    AboutQuantisnow PlusContactJobs
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form SC 13G filed by Xilio Therapeutics Inc.

    4/5/24 4:31:53 PM ET
    $XLO
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $XLO alert in real time by email
    SC 13G 1 d824908dsc13g.htm SC 13G SC 13G

     

     

    UNITED STATES

    SECURITIES AND EXCHANGE COMMISSION

    Washington, D.C. 20549

     

     

    SCHEDULE 13G

    Under the Securities Exchange Act of 1934

    (Amendment No. )*

     

     

    Xilio Therapeutics, Inc.

    (Name of Issuer)

    Common Stock, par value $0.0001 per share

    (Title of Class of Securities)

    98422T100

    (CUSIP Number)

    March 27, 2024

    (Date of Event Which Requires Filing of this Statement)

     

     

    Check the appropriate box to designate the rule pursuant to which this Schedule is filed:

     

    ☐   

    Rule 13d-1(b)

     

    ☒   

    Rule 13d-1(c)

     

    ☐    Rule 13d-1(d)

     

    *

    The remainder of this cover page shall be filled out for a reporting person’s initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter the disclosures provided in a prior cover page.

    The information required in the remainder of this cover page shall not be deemed to be “filed” for purposes of Section 18 of the Securities Exchange Act of 1934 (“Act”) or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).

     

     

     


    CUSIP NO. 98422T100

     

     1   

     NAMES OF REPORTING PERSONS

     

     Gilead Sciences, Inc.

     2  

     CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP (SEE INSTRUCTIONS)

     (a) ☐  (b) ☐

     

     3  

     SEC USE ONLY

     

     4  

     CITIZENSHIP OR PLACE OF ORGANIZATION

     

     Delaware

    NUMBER OF

    SHARES  BENEFICIALLY 

    OWNED BY

    EACH

    REPORTING

    PERSON

    WITH

       5    

     SOLE VOTING POWER

     

     7,345,473(1)

       6   

     SHARED VOTING POWER

     

     0

       7   

     SOLE DISPOSITIVE POWER

     

     7,345,473(1)

       8   

     SHARED DISPOSITIVE POWER

     

     0

     9   

     AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

     

     7,345,473(1)

    10  

     CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES

     

     ☐

    11  

     PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)

     

     19.9%(2)

    12  

     TYPE OF REPORTING PERSON*

     

     CO

     

    (1) 

    Consists of (A) 6,860,223 shares of common stock, par value $0.0001 per share (the “Common Stock”), of Xilio Therapeutics, Inc. (the “Issuer”) issued to the Reporting Person on March 28, 2024 and (B) 485,250 shares of Common Stock issued to the Reporting Person on April 3, 2024.

    (2) 

    Based on 34,473,486 shares of Common Stock issued and outstanding as of March 28, 2024, as disclosed in the Issuer’s annual report on Form 10-K filed with the U.S. Securities and Exchange Commission (the “SEC”) on April 1, 2024, plus (A) 485,250 shares of Common Stock issued to the Reporting Person on April 3, 2024 and (B) 1,953,125 shares of Common Stock issued to other investors on April 2, 2024, based on information provided by the Issuer.


    Item 1(a)    Name of Issuer:
       Xilio Therapeutics, Inc. (the “Issuer”)
    Item 1(b)    Address of Issuer’s Principal Executive Offices:
      

    828 Winter Street, Suite 300

    Waltham, Massachusetts 02451

    Item 2(a)    Name of Person Filing:
       Gilead Sciences, Inc.
    Item 2(b)    Address of Principal Business Office or, if none, Residence:
      

    333 Lakeside Drive

    Foster City, California 94404

    Item 2(c)    Citizenship:
       Delaware
    Item 2(d)    Title of Class of Securities:
       Common Stock, par value $0.0001 per share
    Item 2(e)    CUSIP No.:
       98422T100


    Item 3    If this statement is filed pursuant to Rules 13d-1(b), or 13d-2(b), check whether the person filing is a:

     

    (a)   ☐    Broker or dealer registered under section 15 of the Act (15 U.S.C. 78o);
    (b)   ☐    Bank as defined in section 3(a)(6) of the Act (15 U.S.C. 78c);
    (c)   ☐    Insurance company as defined in section 3(a)(19) of the Act (15 U.S.C. 78c);
    (d)   ☐    Investment company registered under section 8 of the Investment Company Act of 1940 (15 U.S.C 80a-8);
    (e)   ☐    An investment adviser in accordance with § 240.13d-1(b)(1)(ii)(E);
    (f)   ☐    An employee benefit plan or endowment fund in accordance with § 240.13d-1(b)(1)(ii)(F);
    (g)   ☐    A parent holding company or control person in accordance with § 240.13d-1(b)(1)(ii)(G);
    (h)   ☐    A savings associations as defined in Section 3(b) of the Federal Deposit Insurance Act (12 U.S.C. 1813);
    (i)   ☐    A church plan that is excluded from the definition of an investment company under section 3(c)(14) of the Investment Company Act of 1940 (15 U.S.C. 80a-3);
    (j)   ☐    A non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J);
    (k)   ☐    Group, in accordance with § 240.13d-1(b)(1)(ii)(K). If filing as a non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J), please specify the type of institution:      


    Item 4

    Ownership:

    (a) Amount beneficially owned: 7,345,473(1)

    (b) Percent of class: 19.9%(2)

    (c) Number of shares as to which such person has:

    (i) Sole power to vote or direct the vote: 7,345,473(1)

    (ii) Shared power to vote or direct the vote: 0

    (iii) Sole power to dispose or direct the disposition: 7,345,473(1)

    (iv) Shared power to dispose or direct the disposition: 0

     

    (1) 

    Consists of (A) 6,860,223 shares of Common Stock issued to the Reporting Person on March 28, 2024 and (B) 485,250 shares of Common Stock issued to the Reporting Person on April 3, 2024.

    (2) 

    Based on 34,473,486 shares of Common Stock issued and outstanding as of March 28, 2024, as disclosed in the Issuer’s annual report on Form 10-K filed with the SEC on April 1, 2024, plus (A) 485,250 shares of Common Stock issued to the Reporting Person on April 3, 2024 and (B) 1,953,125 shares of Common Stock issued to other investors on April 2, 2024, based on information provided by the Issuer.

     

    Item 5

    Ownership of Five Percent or Less of a Class:

    If this statement is being filed to report the fact that as of the date hereof each of the Reporting Persons has ceased to be the beneficial owner of more than five percent of the class of securities, check the following ☐.

     

    Item 6

    Ownership of More Than Five Percent on Behalf of Another Person:

    N/A

     

    Item 7

    Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on by the Parent Holding Company or Control Person:

    N/A

     

    Item 8

    Identification and Classification of Members of the Group:

    N/A

     

    Item 9

    Notice of Dissolution of Group:

    N/A

     

    Item 10

    Certification:

    By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under § 240.14a-11.


    SIGNATURE

    After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

    Date: April 5, 2024

     

    Gilead Sciences, Inc.
    By:  

    /s/ Andrew D. Dickinson

      Name: Andrew D. Dickinson
      Title: Executive Vice President and Chief Financial Officer
    Get the next $XLO alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $XLO

    DatePrice TargetRatingAnalyst
    12/21/2022$7.00Buy
    Chardan Capital Markets
    1/10/2022$36.00Buy
    HC Wainwright & Co.
    11/16/2021$40.00Buy
    Guggenheim
    11/16/2021$31.00Outperform
    Raymond James
    11/16/2021Outperform
    Cowen & Co.
    11/16/2021$32.00Overweight
    Morgan Stanley
    More analyst ratings

    $XLO
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • Xilio Therapeutics Announces Pipeline and Business Updates and First Quarter 2025 Financial Results

      Updated Phase 2 data to be presented at ASCO for vilastobart, a tumor-activated, Fc-enhanced, anti-CTLA-4, in combination with atezolizumab in patients with metastatic microsatellite stable colorectal cancer (MSS CRC) Advancing multiple masked T cell engager programs utilizing Xilio's novel ATACR and SEECR formats, with first development candidates anticipated in second half of 2025 WALTHAM, Mass., May 08, 2025 (GLOBE NEWSWIRE) -- Xilio Therapeutics, Inc. (NASDAQ:XLO), a clinical-stage biotechnology company discovering and developing tumor-activated immuno-oncology therapies for people living with cancer, today announced pipeline progress and business updates and reported financial resul

      5/8/25 7:30:00 AM ET
      $XLO
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Xilio Therapeutics Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

      WALTHAM, Mass., May 02, 2025 (GLOBE NEWSWIRE) -- Xilio Therapeutics, Inc. (NASDAQ:XLO), a clinical-stage biotechnology company discovering and developing tumor-activated immuno-oncology therapies for people living with cancer, today announced that, effective May 1, 2025, the company granted a non-qualified stock option to purchase 5,000 shares of its common stock to one new employee under Xilio Therapeutics' 2022 Inducement Stock Incentive Plan. The stock options have an exercise price of $0.755 per share, which is equal to the closing price of the company's common stock on May 1, 2025. Each stock option has a ten-year term and will vest as to 25% of the shares underlying the stock option

      5/2/25 4:30:00 PM ET
      $XLO
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Xilio Therapeutics to Present Updated Phase 2 Data for Vilastobart, a Tumor-Activated, Fc-Enhanced Anti-CTLA-4, in Combination with Atezolizumab in Patients with Microsatellite Stable Colorectal Cancer at the 2025 ASCO Annual Meeting

      WALTHAM, Mass., April 23, 2025 (GLOBE NEWSWIRE) -- Xilio Therapeutics, Inc. (NASDAQ:XLO), a clinical-stage biotechnology company discovering and developing tumor-activated immuno-oncology therapies for people living with cancer, today announced plans to present updated data from its ongoing Phase 2 clinical trial investigating vilastobart, a tumor-activated, Fc-enhanced anti-CTLA-4, in combination with atezolizumab (Tecentriq®) in patients with metastatic microsatellite stable colorectal cancer (MSS CRC) at the 2025 American Society of Clinical Oncology (ASCO) Annual Meeting. The conference is being held in Chicago, Illinois from May 30 to June 3, 2025. Presentation DetailsTitle: Vilastob

      4/23/25 4:30:00 PM ET
      $XLO
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $XLO
    Leadership Updates

    Live Leadership Updates

    See more
    • Xilio Therapeutics Announces Pipeline and Business Updates and Fourth Quarter and Full Year 2024 Financial Results

      Additional Phase 2 data for vilastobart, a tumor-activated, Fc-enhanced anti-CTLA-4, in combination with atezolizumab in patients with MSS CRC anticipated in the middle of 2025 Advancing masked T cell engager programs in novel ATACR and SEECR formats for PSMA, CLDN18.2 and STEAP1 Announced collaboration with AbbVie in the first quarter of 2025 to develop novel tumor-activated, antibody-based immunotherapies, including masked T cell engagers WALTHAM, Mass., March 11, 2025 (GLOBE NEWSWIRE) -- Xilio Therapeutics, Inc. (NASDAQ:XLO), a clinical-stage biotechnology company discovering and developing tumor-activated immuno-oncology therapies for people living with cancer, today announced pipe

      3/11/25 7:30:58 AM ET
      $XLO
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Xilio Therapeutics Appoints Caroline Hensley as Chief Legal Officer

      WALTHAM, Mass., Dec. 16, 2024 (GLOBE NEWSWIRE) -- Xilio Therapeutics, Inc. (NASDAQ:XLO), a clinical-stage biotechnology company discovering and developing tumor-activated immuno-oncology therapies for people living with cancer, today announced the appointment of Caroline (Holda) Hensley as chief legal officer. "Caroline is an accomplished lawyer and biotechnology executive who brings a wealth of experience advising public life science companies across all stages of development and commercialization," said René Russo, Pharm.D., president and chief executive officer of Xilio. "Her expertise and strategic insights make her a tremendous addition to our executive team, and we are excited to ha

      12/16/24 7:30:00 AM ET
      $XLO
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Xilio Therapeutics Appoints Aoife Brennan, M.D., and James Shannon, M.D., to its Board of Directors

      WALTHAM, Mass., June 13, 2024 (GLOBE NEWSWIRE) -- Xilio Therapeutics, Inc. (NASDAQ:XLO), a clinical-stage biotechnology company discovering and developing tumor-activated immuno-oncology therapies for people living with cancer, today announced the appointment of Aoife Brennan, M.D., and James Shannon, M.D., to the company's board of directors. "On behalf of the entire board of directors, it is a privilege to welcome Aoife and James, both well-recognized biotech industry veterans, to the board of directors," said Paul Clancy, chair of the board of directors of Xilio Therapeutics. "Their extensive experience spanning all stages of drug development will be invaluable as Xilio progresses its

      6/13/24 4:05:00 PM ET
      $XLO
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $XLO
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • SEC Form 4 filed by Chief Financial Officer Frankenfield Christopher James

      4 - Xilio Therapeutics, Inc. (0001840233) (Issuer)

      4/16/25 4:30:14 PM ET
      $XLO
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 4 filed by PRESIDENT AND CEO Russo Rene

      4 - Xilio Therapeutics, Inc. (0001840233) (Issuer)

      4/16/25 4:30:17 PM ET
      $XLO
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Chief Financial Officer Frankenfield Christopher James converted options into 19,375 shares and sold $6,841 worth of shares (6,954 units at $0.98) (SEC Form 4)

      4 - Xilio Therapeutics, Inc. (0001840233) (Issuer)

      1/3/25 4:15:19 PM ET
      $XLO
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $XLO
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • Amendment: SEC Form SC 13G/A filed by Xilio Therapeutics Inc.

      SC 13G/A - Xilio Therapeutics, Inc. (0001840233) (Subject)

      11/14/24 5:44:28 PM ET
      $XLO
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Amendment: SEC Form SC 13G/A filed by Xilio Therapeutics Inc.

      SC 13G/A - Xilio Therapeutics, Inc. (0001840233) (Subject)

      11/14/24 4:30:23 PM ET
      $XLO
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Amendment: SEC Form SC 13G/A filed by Xilio Therapeutics Inc.

      SC 13G/A - Xilio Therapeutics, Inc. (0001840233) (Subject)

      11/12/24 4:50:36 PM ET
      $XLO
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $XLO
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Large owner Gilead Sciences, Inc. bought $1,830,377 worth of shares (1,759,978 units at $1.04), increasing direct ownership by 24% to 9,105,451 units (SEC Form 4)

      4 - Xilio Therapeutics, Inc. (0001840233) (Issuer)

      12/19/24 4:19:34 PM ET
      $XLO
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Gilead Sciences, Inc. bought $368,790 worth of shares (485,250 units at $0.76), increasing direct ownership by 7% to 7,345,473 units (SEC Form 4)

      4 - Xilio Therapeutics, Inc. (0001840233) (Issuer)

      4/3/24 6:50:01 PM ET
      $XLO
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $XLO
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more

    $XLO
    SEC Filings

    See more
    • Chardan Capital Markets initiated coverage on Xilio Therapeutics with a new price target

      Chardan Capital Markets initiated coverage of Xilio Therapeutics with a rating of Buy and set a new price target of $7.00

      12/21/22 7:57:28 AM ET
      $XLO
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • HC Wainwright & Co. initiated coverage on Xilio Therapeutics with a new price target

      HC Wainwright & Co. initiated coverage of Xilio Therapeutics with a rating of Buy and set a new price target of $36.00

      1/10/22 6:12:33 AM ET
      $XLO
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Guggenheim initiated coverage on Xilio Therapeutics with a new price target

      Guggenheim initiated coverage of Xilio Therapeutics with a rating of Buy and set a new price target of $40.00

      11/16/21 9:07:16 AM ET
      $XLO
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form EFFECT filed by Xilio Therapeutics Inc.

      EFFECT - Xilio Therapeutics, Inc. (0001840233) (Filer)

      5/9/25 12:15:09 AM ET
      $XLO
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 10-Q filed by Xilio Therapeutics Inc.

      10-Q - Xilio Therapeutics, Inc. (0001840233) (Filer)

      5/8/25 4:31:19 PM ET
      $XLO
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Xilio Therapeutics Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits

      8-K - Xilio Therapeutics, Inc. (0001840233) (Filer)

      5/8/25 7:35:12 AM ET
      $XLO
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $XLO
    Financials

    Live finance-specific insights

    See more
    • Xilio Therapeutics Announces Multiple Masked T Cell Engager Programs

      Also entered into collaboration and option agreement with AbbVie to develop novel tumor-activated immunotherapies, including masked T cell engagers, with $52.0 million in upfront payments Extended anticipated cash runway into the first quarter of 2026 Company to host investor conference call and webcast today at 8:30 am ET WALTHAM, Mass., Feb. 12, 2025 (GLOBE NEWSWIRE) -- Xilio Therapeutics, Inc. (NASDAQ:XLO), a clinical-stage biotechnology company discovering and developing tumor-activated immuno-oncology therapies for people living with cancer, today announced three wholly-owned preclinical programs for masked T cell engagers targeting prostate-specific membrane antigen (PSMA), claudi

      2/12/25 7:35:00 AM ET
      $XLO
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • AbbVie and Xilio Therapeutics Announce Collaboration and Option Agreement to Develop Novel Tumor-Activated Immunotherapies

      Collaboration will combine AbbVie's oncology expertise and Xilio's proprietary tumor-activation technology to develop novel immunotherapies, including masked T-cell engagersXilio to host investor conference call and webcast today at 8:30 am EST NORTH CHICAGO, Ill. and WALTHAM, Mass., Feb. 12, 2025 (GLOBE NEWSWIRE) -- AbbVie (NYSE:ABBV) and Xilio Therapeutics, Inc. (NASDAQ:XLO), a clinical-stage biotechnology company discovering and developing tumor-activated immuno-oncology therapies for people living with cancer, today announced a collaboration and option-to-license agreement to develop novel tumor-activated, antibody-based immunotherapies, including masked T-cell engagers, leveraging X

      2/12/25 7:33:00 AM ET
      $ABBV
      $XLO
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • AbbVie and Xilio Therapeutics Announce Collaboration and Option Agreement to Develop Novel Tumor-Activated Immunotherapies

      Collaboration will combine AbbVie's oncology expertise and Xilio's proprietary tumor-activation technology to develop novel immunotherapies, including masked T-cell engagers Xilio to host investor conference call and webcast today at 8:30 am ESTNORTH CHICAGO, Ill. and WALTHAM, Mass., Feb. 12, 2025 /PRNewswire/ -- AbbVie (NYSE:ABBV) and Xilio Therapeutics, Inc. (NASDAQ:XLO), a clinical-stage biotechnology company discovering and developing tumor-activated immuno-oncology therapies for people living with cancer, today announced a collaboration and option-to-license agreement to develop novel tumor-activated, antibody-based immunotherapies, including masked T-cell engagers, leveraging Xilio's p

      2/12/25 7:30:00 AM ET
      $ABBV
      $XLO
      Biotechnology: Pharmaceutical Preparations
      Health Care